SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Abgenix, Inc. (ABGX) -- Ignore unavailable to you. Want to Upgrade?


To: nigel bates who wrote (582)12/22/2005 1:18:08 PM
From: tuck  Respond to of 590
 
>>WASHINGTON (Dow Jones)--The following provides information on selected merger and acquisition deals. All figures are updated by Dow Jones Newswires, with share prices as of 10 a.m. Eastern Thursday.

Annualized rate of return is based on Thursday's date and the expected closing date and isn't compounded. Expected closing dates are compiled from company statements and reports, and when a time period is cited, that information is provided with that time period's midpoint date, which was used to make the annualized return calculation.

Deals are listed alphabetically by acquirer, and spreads don't include dividend or interest payments. "Current discount" refers to the discount at which the target company's stock is trading compared with the acquirer's offer.

If the target stock is trading higher than the offer, the amount is referred to as the "current premium." Deal values don't include the assumption of debt. (Dow Jones 202-862-3545)

Stock price data source: Thomson One <<

snip

Amgen Inc. (AMGN), Abgenix Inc. (ABGX)

Current discount: $0.96 or 4.27%
Acquirer: AMGN
Target: ABGX
Offer per share: $22.50 cash
Value of outstanding common equity: $2,038,500,000
Target share price: $21.54
Acquirer share price: $79.90
Expected closing: First Quarter 2006 2/15/2006
Annualized gain: 29.58% <<

snip

Might have to buy me some. Me thinks the risk of the deal falling through is negligible.

Cheers, Tuck